Menu
← Oncology Approval Tracker
FDA DECISION ·
Libtayo + platinum-based chemotherapy
cemiplimab-rwlc plus platinum-based chemotherapy · Regeneron
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line therapy with platinum-based chemotherapy for adults with locally advanced NSCLC unsuitable for resection or definitive chemoradiation, or metastatic NSCLC, without EGFR, ALK or ROS1 aberrations.
LAMPGEN ANALYSIS
Why it matters
The action extends cemiplimab use to a first-line combination with a platinum regimen.
What research teams should watch
Document molecular testing, stage and reasons for ineligibility for definitive local treatment when applicable.
PRIMARY RECORDS